Recon: AbbVie to buy Alzheimer’s biotech Aliada for $1.4B; Philips slashes sales forecast after slump in China

• How a Donald Trump presidency would change health care, from Medicaid to the CDC (STAT)
• Feud between Prime and Tessera, two gene-editing companies, spills out into public (STAT)
• A drug may cause problems with chemotherapies in cancer patients with obesity. Many doctors are in the dark (STAT)
• AbbVie makes $1.4B acquisition of Alzheimer's biotech (Endpoints)
• Gene Therapies: Bluebird Bio Presses US FDA To Reverse Denial Of Lyfgenia Priority Review Voucher (Pink Sheet)
• Medicare Plans Should Halt Off-Label Avastin Step Therapy Amid Supply Disruption, CMS Told (Pink Sheet)
• Pfizer management looks to show turnaround as Starboard looms (Reuters)

• BeiGene executive reportedly under investigation in China (Endpoints)
• Future EU Health Commissioner Pledges Action On Pharma Reform, Shortages & Biotech (Pink Sheet)
• Cross-Country HTA Collaboration To Focus On Health Economics & RWE (Pink Sheet)
• Industry Wants UK Clinical Trial Diversity Plans To ‘Work Alongside’ Global Regulations (Pink Sheet)
• Italy Sets Up Project To ‘Break Industry Monopoly’ On Drug Information (Pink Sheet)
• European Parliament Wants EC’s MDR Revision Proposals By End Of March 2025 (MedTech Insight)
• India's Sun Pharma beats Q2 profit view on higher demand for specialty drugs (Reuters)

• Novartis, Seagen veteran David Epstein is back, leading a new cancer startup (STAT)
• Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs (Reuters)
• Biogen appoints insider as CFO after Michael McDonnell to retire next year (Reuters)
• Blood-based biomarkers for Alzheimer’s present complex challenges to health care system (STAT)
• Synaffix, industry's ADC partner of choice, spins out a startup pipeline (Endpoints)
• Biogen's full Ph2 data for IgA nephropathy drug; Sanofi invests in obesity biotech (Endpoints)
• HOPO Therapeutics wins up to $226M BARDA contract for heavy metal poisoning research (Endpoints)

• Philips cuts sales forecast after ‘significant deterioration’ in China (MedTech Dive)
• FDA advises clinicians to stop using Hologic radiographic markers (MedTech Dive)
• Thoughtful implementation, ongoing monitoring key to safe health AI (MedTech Dive)
• Dexcom chief commercial officer to retire (MedTech Dive)
• Edwards’ TAVR sales faced ongoing hospital constraints in Q3 (MedTech Dive)
• Medtronic wins FDA approval for Affera mapping and ablation system (MedTech Dive)
• Swiss hearing aid maker Sonova resumes supplying Costco, source says (Reuters)

• The dropped call that took down Centene’s Medicare Advantage star ratings (STAT)
• For Rare and Rapidly Progressing Disease US FDA Has Heard ‘Well and Clear’ Placebo Is Unacceptable (Pink Sheet)
• Opinion: The Fog at CDRH Is Lifting (a Bit) (MedTech Insight)
• Homeopathic Industry Group Wants Court to Exclude It From FDA’s Enforcement Plans (FDA Law Blog)